Samantha Oakes retweeted
It's the Final Countdown to the @ANZUPTrials #ANZUP26 ASM. In just over a week we are coming to #Adelaide! View the program here: anzup.org.au/asm-program/. It's not too late to register: anzup.org.au/asm-registrati…
@BizEventsAdl @AdelaideCC @DrCraigGedye @LisaButler5 @Prof_IanD
@BizEventsAdl @AdelaideCC @DrCraigGedye @LisaButler5 @Prof_IanD
0
3
3
347
Samantha Oakes retweeted
The wait is almost over! The @ANZUPtrials #ANZUP26 ASM is coming to #Adelaide in just under 2 weeks' time! View the program here: anzup.org.au/asm-program/. It's not too late to register: anzup.org.au/asm-registrati… @BizEventsAdl @AdelaideCC @DrCraigGedye @LisaButler5 @Prof_IanD
0
3
7
270
Samantha Oakes retweeted
@SamanthaROakes @scserendipity1 @ASCO @myESMO @NatureMedicine @ANZUPtrials Thank you, Sam. Indeed, @ANZUPtrials has been leading by example, including creating lay summaries for patients!
1
2
4
324
Samantha Oakes retweeted
The most important paper of #ASCO26 just dropped in Nature Med! Or any other @ASCO or @myESMO meetings to be honest. When you hear someone present “the toxicities were acceptable”, please respond “downplaying toxicities is not acceptable”. Thank you @NatureMedicine for publishing .co/ydAfoTWVJ0
18
96
390
57,602
Missing being at #ASCO26 but at least we have the fabulous @declangmurphy summarising the outcomes of this practice changing study!
0
2
7
1,349
Samantha Oakes retweeted
Masterful discussion by @declangmurphy of #PROTEUS in #ASCO26 LBA1 plenary, complete with an incidental and effective drive by swipe at inappropriate ARPI switch controls. And nods to #ENZARAD, and to @ANZUPtrials @ChrisSweens1 proposed freedom from clinical detriment endpoint.
0
4
12
1,324
Samantha Oakes retweeted
Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study. #ASCO25 Abstract
htThis ENZAMET biomarker 🎯analysis evaluated whether Decipher Genomic Classifier (DGC) scores predict benefit from adding docetaxel💊 (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer. Among 634 patients, high DGC scores (>0.85) were associated with worse overall survival on ADT plus ENZ alone, but this adverse prognosis was negated by adding DOC.
Findings suggest DGC may identify patients most likely to benefit from triplet therapy, particularly in high-volume disease.
@ChrisSweens1
@ChrisSweens1 @MartinStockler @anis_a_hamid @AzadOncology @Davicioni @AttardLab @Prof_IanD
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists
0
5
11
1,683
Samantha Oakes retweeted
Are you coming to the #ANZUP26 ASM in #Adelaide this June? @ANZUPtrials have partnered with @Qantas to offer special flight discounts. Read more on our website: anzup.org.au/asm-registrati… @BizEventsAdl @AdelaideCC
0
5
8
375
Samantha Oakes retweeted
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
euoncology.europeanurology.com/article/S2588-…
In ENZAMET, a post hoc multistate analysis of 1125 men with metastatic ate cancer, discordant radiographic progression without PSA rise occurred in 10% of patients and accounted for 30% of progression events. Discordant progression was associated with worse overall survival.
Enzalutamide significantly delayed and reduced risks of discordant and other progression, supporting routine imaging beyond PSA-based monitoring to better detect early radiographic disease progression in clinical practice settings worldwide. #ProstateCancer
Andrisha-Jade Inderjeetha
Andrew Martin
@scserendipity1
@mfrydenberg
Lisa G. Horvath @COBLH
@GavinMarx1
@crashimminent
@MargaretMcJann1
@SandhuShahneen
@fverabadillo
@MartinStockler
@ChrisSweens1
@Prof_IanD
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists
0
1
3
318
A wonderful ongoing partnership 🇦🇺❤️😍🇮🇪
Great to meet @ANZUPtrials at #ESMO25 to discuss current collaborations and new opportunities in GU cancer trials.
📸 @SamanthaROakes @AngelaClaytonL1 Jactina Marron @mraheelhashim
Working together to bring more studies to patients in Ireland 🇮🇪 🤝🇦🇺🇳🇿 @myESMO
0
0
0
55
Samantha Oakes retweeted
The Best of GU Evening Symposium is a collaboration between @ANZUPtrials and @USANZUrology – featuring highlights from the #ANZUP25 ASM, #GU25, #ASCO25, #ESMO25 and UAA Congress 2025. Spaces are limited so register now! @Prof_IanD anzup.org.au/best-of-gu-onc…
0
4
4
618
Samantha Oakes retweeted
The 4th Asia Pacific Advanced Prostate Cancer Consensus Meeting: How much has changed? Many questions answered, yet so many known unknowns remain. @ANZUPtrials @USANZUrology @BJUIjournal @bjuiknowledge @Uroweb
0
6
18
1,065
Samantha Oakes retweeted
That’s a wrap of the @ANZUPtrials #APCCC APAC Satellite Conference. Many thanks to Convenors @Prof_IanD @RenuEapen @EdChiongUROonc & @declangmurphy. Also thanks to our sponsors - Gold: @Bayer @JNJNews @Novartis, Supporters: @AstellasUS @pfizer #APCCCinAPAC25 #ProstateCancer
1
4
14
1,299
Samantha Oakes retweeted
Excellent editorial - I agree with every word.
Our new editorial just published in @BMJOncology led by @lateuwen where we discuss the use of inferior control arm in cancer drug trials run in LMICs. bmjoncology.bmj.com/content/4/1/e0…
1
3
14
2,154
Samantha Oakes retweeted
Presented at the ANZUP RCC IGW in Sydney. Grateful for the opportunity to share an idea aimed at improving RCC care. Excited about the potential for future collaboration. @ANZUPtrials @MyUrologyAssoc @UiTMMedic @MonashHealth @USANZUrology
1
4
13
761
The fabulous @DrL_Krieger and myself twinning at the @ANZUPtrials Kidney Cancer Ideas Generation Workshop. Such a great day full of great ideas and conversations - towards our vision of living life without fear of cancer. Sydney Sock Project 🍑
1
1
4
251
Samantha Oakes retweeted
Congratulations @ANZUPtrials #ENZAp @TheLancetOncol publication by @drlouiseemmett & the entire team @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD
PSMA-PET total tumour volume is prognostic for overall survival in mCRPC.
thelancet.com/journals/lanon…
PSMA-PET value extends beyond selection for PSMA-RLT therapy in metastatic prostate cancer.
urotoday.com/video-lectures…
@ANZUPtrials @trialscentre @PCFnews @MovemberAUS
0
1
8
309
Samantha Oakes retweeted
A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for overall survival and predictive for benefit of Lu-177 PSMA-617.
Great data from @ANZUPtrials ENZA-P led by @drlouiseemmett
authors.elsevier.com/c/1lWie5EIIgTS9~
ncol #theranostics
Great data from @ANZUPtrials ENZA-P led by @drlouiseemmett
authors.elsevier.com/c/1lWie5EIIgTS9~
ncol #theranostics
2
31
91
4,669
Samantha Oakes retweeted
Wonderful collaborative efforts w landscape of @ANZUPtrials for the spectrum of #prostatecancer! #LisaHorvath @AzadOncology @DrMHofman @ChrisSweens1 @Prof_IanD
0
4
17
1,402
Samantha Oakes retweeted
Correlative work is possibly our most important tool in clinical trials. Congrats to @EdmondMKwan & #TheraP team for this insightful pub on ctDNA burden & PTEN loss predicting responses to 177Lu-PSMA & reminding us of his why - the patients behind the data. @ANZUPtrials #ANZUP25
0
9
18
1,687